GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » EV-to-FCF

China Resources Pharmaceutical Group (HKSE:03320) EV-to-FCF : 3.09 (As of May. 17, 2024)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, China Resources Pharmaceutical Group's Enterprise Value is HK$42,014 Mil. China Resources Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$13,582 Mil. Therefore, China Resources Pharmaceutical Group's EV-to-FCF for today is 3.09.

The historical rank and industry rank for China Resources Pharmaceutical Group's EV-to-FCF or its related term are showing as below:

HKSE:03320' s EV-to-FCF Range Over the Past 10 Years
Min: 2.96   Med: 10.33   Max: 41.09
Current: 2.96

During the past 11 years, the highest EV-to-FCF of China Resources Pharmaceutical Group was 41.09. The lowest was 2.96. And the median was 10.33.

HKSE:03320's EV-to-FCF is ranked better than
94.05% of 521 companies
in the Drug Manufacturers industry
Industry Median: 24.13 vs HKSE:03320: 2.96

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), China Resources Pharmaceutical Group's stock price is HK$6.19. China Resources Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.667. Therefore, China Resources Pharmaceutical Group's PE Ratio for today is 9.28.


China Resources Pharmaceutical Group EV-to-FCF Historical Data

The historical data trend for China Resources Pharmaceutical Group's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group EV-to-FCF Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.57 9.51 6.75 8.99 6.39

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.75 - 8.99 - 6.39

Competitive Comparison of China Resources Pharmaceutical Group's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's EV-to-FCF falls into.



China Resources Pharmaceutical Group EV-to-FCF Calculation

China Resources Pharmaceutical Group's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=42014.342/13581.631
=3.09

China Resources Pharmaceutical Group's current Enterprise Value is HK$42,014 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$13,582 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Pharmaceutical Group  (HKSE:03320) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

China Resources Pharmaceutical Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.19/0.667
=9.28

China Resources Pharmaceutical Group's share price for today is HK$6.19.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.667.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


China Resources Pharmaceutical Group EV-to-FCF Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines